The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal antibody product — but it may not be enough for immunocompromised populations. Pemivibart (Pemgarda, Invivyd) was granted emergency use authorization by the FDA in March 2024 for injectable use every 3 months in adults and adolescents aged 12 years or older who weigh
We would like to understand better what advocacy activities are important to you.Please complete our brief survey to help us focus on what matters most…
The JBJS Quiz of the Month is a collection of 10 relevant questions from each orthopaedic subspecialty. The questions are drawn from JBJS Clinical Classroom,…
Enrollment is underway for a clinical trial that will evaluate whether smartwatch technology can allow for earlier detection of lymphedema.Lymphedema — a common complication that…
There is a paucity of research on the demographic trends of orthopedic and plastic hand surgery fellows. The purpose of this study was to ascertain…
Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of…
Few researchers can claim to be a pioneer in their field quite like Teresa K. Woodruff, PhD. While serving as the basic science director at…
You’ve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your…
o participants’ beliefs and feelings that might explain why fears and worries persist after a PE-grounded intervention for CLBP. Methods: We conducted a qualitative study…
Discontinuing adalimumab led to higher rates of recurrence of uveitis, arthritis, or both in patients with previously controlled juvenile idiopathic arthritis-associated uveitis. However, all patients…
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo,…
